Insight Molecular Diagnostics Inc.
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q2 23 | Q3 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -6.8% | -13.0% | +5.3% | -6.0% | -50.0% | +72.1% | -16.3% | -13.0% | -41.4% | +57.0% | -27.2% | |
| – | -19.4% | -61.4% | +52.5% | -51.9% | +145.3% | +208.4% | -26.0% | -20.3% | -28.4% | +99.4% | -32.7% | |
| – | -20.6% | -59.5% | +65.9% | -63.7% | +156.8% | +259.3% | -21.7% | -23.0% | -38.0% | +143.5% | -37.0% | |
| – | -20.5% | -60.8% | +65.9% | -63.7% | +156.8% | +259.3% | -21.7% | -23.0% | -38.0% | +143.5% | -37.0% | |
| – | +9.7% | -91.4% | -47.2% | +145.9% | +671.8% | +119.5% | -85.5% | -49.6% | +337.2% | -86.1% | +22.3% | |
| – | -27.2% | – | – | – | +76.7% | +12.0% | +51.0% | -32.0% | -5.3% | -14.3% | -45.8% | |
| – | 0.0% | -0.1% | 0.0% | 0.0% | -74.2% | 0.0% | +0.0% | +0.0% | – | – | – | |
| – | +12.3% | +22.8% | -3.8% | +16.3% | -21.7% | +5.9% | -1.4% | +7.5% | +7.7% | -10.7% | -0.7% | |
| – | +4.8% | +3.7% | -13.6% | +26.3% | -20.0% | +33.1% | -31.3% | +15.2% | +57.6% | -0.6% | -14.3% | |
| – | -2.3% | +14.0% | +25.3% | +24.7% | +0.9% | +8.4% | +9.7% | +3.8% | +13.1% | -2.5% | -3.0% | |
| – | +29.8% | -20.1% | +15.7% | -17.0% | +161.4% | +0.0% | -44.0% | -17.3% | +140.9% | -36.5% | +15.9% | |
| – | -22.3% | -55.0% | +34.2% | -57.2% | -226.4% | – | -89.3% | -937.5% | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +2.1% | +0.1% | +55.7% | +6.6% | +26.7% | +47.8% | +24.6% | +0.0% | -4.9% | +13.3% | +6.5% |
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.